Baumgart Daniel C, Vierziger Karin, Sturm Andreas, Wiedenmann Bertram, Dignass Axel U
Department of Medicine, Division of Hepatology & Gastroenterology, Charité Medical Center-Virchow Hospital, Medical School of the Humboldt-University of Berlin, Germany.
Scand J Gastroenterol. 2005 Aug;40(8):958-64. doi: 10.1080/00365520510015854.
Treatment with 5-aminosalicylic acid (5-ASA) derivatives is one of the main principles in the therapy of uncomplicated mild to moderate inflammatory bowel diseases (IBD). The beneficial effect of 5-ASA in the treatment of IBD is attributed to its anti-inflammatory and anti-oxidant properties within the inflamed gut. The aim of this study was to investigate whether 5-ASA also modulates intestinal epithelial wound repair in vitro.
The effects of 5-ASA on cell migration and proliferation, two key processes in mucosal healing, were studied in the non-transformed small-intestinal epithelial cell line IEC-6 using an in vitro wounding model and colorimetric MTT assays. Furthermore, the effects of 5-ASA on epithelial cell viability were determined by Trypan blue exclusion and flow cytometry-based cell cycle analysis.
Clinically relevant concentrations of 5-ASA caused a significant dose-dependent enhancement of epithelial cell migration and proliferation in vitro. An about 2-fold enhancement of intestinal epithelial cell proliferation and migration was observed for pharmacological doses of 100 microg/ml 5-ASA. Neutralizing antibodies against TGFbeta did not modulate 5-ASA effects on IEC-6 cell proliferation and migration, indicating that the effects of 5-ASA were TGFbeta independent. Trypan blue viability tests and cell cycle analysis did not reveal any toxic or apoptotic effects of pharmacological 5-ASA concentrations on IEC-6 cells.
5-ASA promotes the rapid re-establishment of mucosal integrity in vitro by enhancing epithelial restitution and proliferation, suggesting that 5-ASA in addition to the well-characterized effects on the intestinal inflammatory cascade may also directly stimulate epithelial wound healing.
使用5-氨基水杨酸(5-ASA)衍生物进行治疗是单纯性轻至中度炎症性肠病(IBD)治疗的主要原则之一。5-ASA在IBD治疗中的有益作用归因于其在炎症肠道内的抗炎和抗氧化特性。本研究的目的是调查5-ASA在体外是否也能调节肠道上皮伤口修复。
使用体外创伤模型和比色MTT法,在未转化的小肠上皮细胞系IEC-6中研究5-ASA对细胞迁移和增殖这两个黏膜愈合关键过程的影响。此外,通过台盼蓝排斥试验和基于流式细胞术的细胞周期分析来确定5-ASA对上皮细胞活力的影响。
临床相关浓度的5-ASA在体外引起上皮细胞迁移和增殖的显著剂量依赖性增强。对于100μg/ml 5-ASA的药理剂量,观察到肠道上皮细胞增殖和迁移增强了约2倍。针对转化生长因子β(TGFβ)的中和抗体并未调节5-ASA对IEC-6细胞增殖和迁移的影响,表明5-ASA的作用不依赖于TGFβ。台盼蓝活力测试和细胞周期分析未显示药理浓度的5-ASA对IEC-6细胞有任何毒性或凋亡作用。
5-ASA通过增强上皮修复和增殖促进体外黏膜完整性的快速重建,这表明5-ASA除了对肠道炎症级联反应有明确的作用外,还可能直接刺激上皮伤口愈合。